Clinical trial

Scientist in laboratory
#Clinical trial #Dicot Pharma #Investigational New Drug (IND)

FDA approves trial of erectile dysfunction treatment 

The US Food and Drug Administration (FDA) has granted Dicot Pharma approval to roll out the Phase IIb study of a treatment for erectile dysfunction.  The approval follows an Investigational New Drug (IND) Application submitted to the FDA, with the trial evaluating LIB-01 now set to commence in the US.  Dicot Pharma says LIB-01… Read More

#News #Regulatory

#AI #ASCO #Cancer research #Clinical trial #Combination therapy #Data science #GLP-1 #Incyte #MHRA #Myeloma #Obesity #Oncology #UK #Ulcerative colitis (UC) #Weight loss

DDW Highlights: 30 June 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, researchers uncovered clues explaining risks of heart disease, lung disease, Covid-19 and… Read More

#Podcasts

Doctor examining brain MRI
#Clinical trial #Multiple sclerosis #Neurology #Pheno Therapeutics

Pheno Therapeutics heads towards human testing of MS therapy

Biotechnology company Pheno Therapeutics has announced that the US Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for its lead therapeutic candidate PTD802 targeting multiple sclerosis (MS). The clearance follows a clinical trial authorisation (CTA) from the UK’s MHRA at the start… Read More

#News

Alopecia
#Absci #Alopecia #Clinical trial

Absci reports positive data from Phase I alopecia trial 

Biopharmaceutical company Absci has reported positive data from the Phase I trial of its alopecia treatment.  ABS-201, an investigational anti-prolactin receptor (PRLR) antibody, was evaluated in a first-in-human, randomised, double-blind, placebo-controlled study in 32 healthy volunteers with and without androgenetic alopecia (AGA).  The medication proved to be well-tolerated across… Read More

#News

#AI #ASCO #Cancer research #Clinical trial #Combination therapy #Data science #GLP-1 #Incyte #MHRA #Myeloma #Obesity #Oncology #UK #Ulcerative colitis (UC) #Weight loss

DDW Highlights: 23 June 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, results showed the new Wegovy pill could help patients lose 17% of… Read More

#Podcasts

#AI #ASCO #Cancer Research UK #Clinical trial #Combination therapy #Data science #GLP-1 #Incyte #MHRA #Myeloma #Obesity #Oncology #UK #Ulcerative colitis (UC) #Weight loss

This week in Drug Discovery (15 June – 19 June) 

News round-up for 15 June – 19 June by Bruno Quinney, Content Team at DDW.  This week, results show the new Wegovy pill could help patients lose 17% of their body weight. Elsewhere, advances have been made in both cancer treatment and cancer research.  The top stories:     … Read More

#News

Leukaemia
#Acute Myeloid Leukaemia #Clinical trial

CERo reports positive data from AML Phase I trial 

CERo Therapeutics has reported encouraging data from a Phase I trial evaluating a treatment for haematologic malignancies in acute myeloid leukaemia (AML).  In the CERTAIN-T trial, a patient with multiple refractory AML – who had not previously achieved disease control sufficient to enable allogeneic stem cell transplantation – showed 7% bone… Read More

#News

Ovarian cancer cells
#Clinical trial #Immunology / Virology & Vaccines #Mayo Clinic #Ovarian cancer

Ovarian cancer vaccine with 40% survival rate to be advanced 

A new agreement is set to advance a vaccine for ovarian cancer which has shown 40% cancer-free survival rates.  Biotechnology company CellxLife has entered an agreement with Mayo Clinic for the dendritic cell vaccine, which reported the 40% 10-year cancer-free survival rate in a Phase I Mayo Clinic study compared to the… Read More

#Business & Investment #Cancer Research #News

Myeloma
#Clinical trial #Combination therapy #Myeloma

Therapy enables 89% survival rate in myeloma patients 

A combination treatment has demonstrated strong survival rates in patients with earlier-line relapsed or refractory multiple myeloma.  Talvey (talquetamab), a GPRC5D bispecific antibody, in combination with daratumumab with or without pomalidomide showed a progression-free survival rate of up to 81.3% versus standard of care (51.2%) and an overall survival… Read More

#Cancer Research #News

Blood tests in laboratory
#Clinical trial #Ulcerative colitis (UC)

Ulcerative colitis treatment shows best-in-class potential 

An anti-TL1A has demonstrated its potential to be a best-in-class treatment for ulcerative colitis.  Biotechnology company Spyre Therapeutics reported results from the Phase II SKYLINE trial evaluating SPY002, an extended half-life investigational antibody targeting TL1A. TL1A is an upstream cytokine implicated in chronic inflammation and fibrosis in inflammatory… Read More

#News

#Cancer research #Clinical trial #Drug discovery #Francis Crick Institute #Funding #Genetic profiling #GLP-1 #Lung cancer #MHRA #National Institute for Health and Care Research #Obesity #Oncology #Rare disease #Regulatory #The Royal Marsden NHS Foundation Trust #University College London #Weight loss

DDW Highlights: 16 June 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, new research showed anti-IL-1β drugs could prevent lung cancer. Elsewhere, the… Read More

#Podcasts

MRI showing glioblastoma
#Brain cancer #Clinical trial #PhoreMost

PhoreMost advances brain cancer programme to trial  

PhoreMost has announced a treatment for brain cancers as its lead programme, also appointing Dr Gabriel Fox as Chief Medical Officer.  The biotechnology company will progress PMC-001, a next-generation, small molecule microtubule targeting agent (MTA) for primary and secondary brain cancers, towards Phase I clinical trial.  PMC-001 is… Read More

#Cancer Research #News

#Cancer research #Clinical trial #Drug discovery #Funding #Genetic profiling #GLP-1 #Lung cancer #MHRA #National Institute for Health and Care Research #Obesity #Oncology #Rare disease #Regulatory #The Francis Crick Institute #The Royal Marsden NHS Foundation Trust #University College London #Weight loss

This week in Drug Discovery (8 – 12 June) 

News round-up for 8 – 12 June by Bruno Quinney, Content Team at DDW.  This week, new research suggests anti-IL-1β drugs could prevent lung cancer. Elsewhere, the UK is set to benefit from specialised blood tests and funding for researchers.   The top stories:   … Read More

#News

#Antibiotics #Clinical trial

Fungus-derived compounds could treat aggressive cancer 

Researchers have identified chemical compounds derived from a fungus that could help treat an aggressive cancer, the Journal of Antibiotics reports.  The compounds, named paramyfurans A and B and paramylactone, were extracted from a fungal strain called Paramyrothecium sp. BF-1049. They were tested against three mesothelioma cell lines in a laboratory setting, with… Read More

#Cancer Research #Editor's Choice #News

Scientist looking through microscope
#Cancer research #Clinical trial #Genetic profiling #The Royal Marsden NHS Foundation Trust #UK

UK cancer patients to benefit from genetic testing rollout 

Hundreds of UK cancer patients will benefit from a rollout of specialised blood tests, providing improved access to genetic testing and personalised therapies.  The Royal Marsden, who are partnering with Guardant Health, will provide circulating tumour DNA (ctDNA) molecular profiling, using the Guardant360 Liquid assay powered by Infinity.   These… Read More

#News

Chronic gout
#Clinical trial #Crystalys Therapeutics #Gout

Crystalys doses first patients in Phase II gout trial 

Crystalys Therapeutics has dosed the first patients in a Phase II trial evaluating a treatment for difficult-to-treat gout.  The trial will evaluate dotinurad, a next-generation, once daily, oral URAT1 inhibitor with the potential to deliver best-in-class safety and efficacy for the treatment of gout, particularly in patients with limited treatment… Read More

#News